Merck Beats Q1 EPS Estimates, Raises Full-Year Guidance, and Highlights Strong Pipeline Progress

summarizeSummary

Merck reported better-than-expected Q1 adjusted earnings and raised its full-year sales and EPS guidance, driven by strong product performance and significant pipeline advancements, including new drug approvals and a strategic acquisition.

check_boxKey Events

• Strong Q1 Financials

  Reported Q1 adjusted loss per share of $1.28, exceeding analyst estimates, with total sales growing 5% to $16.3 billion, despite a $3.62 per share charge for the Cidara acquisition.

• Raised Full-Year Guidance

  Increased the midpoint of its 2026 sales outlook to $65.8-$67.0 billion and non-GAAP EPS guidance to $5.04-$5.16, reflecting a positive outlook.

• Key Regulatory Approvals

  Received U.S. FDA approval for IDVYNSO, a new oral HIV-1 treatment, and achieved multiple oncology regulatory milestones for KEYTRUDA.

• Pipeline Progress

  Announced positive Phase 3 results for enlicitide in LDL-C and advanced WINREVAIR for pulmonary hypertension, alongside other clinical developments.

auto_awesomeAnalysis

Merck reported a Q1 adjusted loss per share of $1.28, which was better than analyst estimates, despite including a significant one-time charge of $3.62 per share related to the acquisition of Cidara Therapeutics. Total worldwide sales grew 5% to $16.3 billion, driven by strong performance in oncology, animal health, and new product launches. The company raised the midpoint of its full-year 2026 sales guidance to $65.8 billion - $67.0 billion and its non-GAAP EPS guidance to $5.04 - $5.16, signaling confidence in its operational performance and pipeline. Key pipeline advancements include the FDA approval of IDVYNSO for HIV-1, multiple regulatory milestones for KEYTRUDA in oncology, positive Phase 3 results for enlicitide in LDL-C, and advancing WINREVAIR for pulmonary hypertension. The recently announced acquisition of Terns Pharmaceuticals, expected to close in May, will further expand the hematology pipeline with TERN-701.